Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHMT2 | P34897 | 7/20 | 0.76 |
| ▸ | SHMT1 | P34896 | 6/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31057953 | 1.00 | SHMT2 (0.76) | SHMT2SHMT1KDM4ESMN1; SMN2GAA | |
| SCHEMBL20255445 | 0.87 | SHMT2 (0.74) | SHMT2SHMT1KDM4ESMN1; SMN2GAA | |
| SCHEMBL21560039 | 0.86 | SHMT2 (0.72) | SHMT2SHMT1KDM4EGAAALDH1A1 | |
| SCHEMBL30163381 | 0.86 | SHMT1 (1.00) | SHMT2SHMT1KDM4EGAAALDH1A1 | |
| SCHEMBL20242167 | 0.86 | SHMT1 (1.00) | SHMT2SHMT1KDM4EGAAALDH1A1 | |
| SCHEMBL9555459 | 0.86 | KDM4E (0.71) | SHMT2SHMT1KDM4ESMN1; SMN2GAA | |
| SCHEMBL21560041 | 0.86 | SHMT2 (0.67) | SHMT2SHMT1KDM4ESMN1; SMN2GAA | |
| SCHEMBL21560188 | 0.86 | KDM4E (0.75) | SHMT2SHMT1KDM4ESMN1; SMN2GAA | |
| SCHEMBL20255560 | 0.86 | SHMT2 (0.66) | SHMT2SHMT1KDM4ESMN1; SMN2GAA | |
| SCHEMBL21560035 | 0.84 | SHMT1 (1.00) | SHMT2SHMT1KDM4ESMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11091451-B2 | SHMT inhibitors and uses thereof | RAZE THERAPEUTICS, INC. (US) | 2021-08-17 | — | — | US | disclosed |
| US-20190345119-A1 | SHMT INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2019-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11091451-B2 | SHMT inhibitors and uses thereof | SHMT1, SHMT2, BHMT | SHMT2 2/4885SHMT1 1/4885KDM4E 344/4885 |
| US-20190345119-A1 | SHMT INHIBITORS AND USES THEREOF | SHMT1, SHMT2, BHMT | SHMT2 2/4885SHMT1 1/4885KDM4E 344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.